CELL INTELLIGENCE · 肿瘤细胞治疗研究

抗 BCMA CAR-NK 细胞显示出对骨髓瘤细胞增强的溶细胞和分泌反应

Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells.

利用 CAR-NK 细胞对抗多发性骨髓瘤：当前格局与未来方向

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

CAR-NK 疗法正从一种有前景的概念演变为针对 MM 的现实治疗平台。

抗 BCMA-CAR-IL15 NK 细胞阻止多发性骨髓瘤在骨髓中生长但随后出现髓外疾病

Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary disease.

多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述

State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.

多发性骨髓瘤中的 CAR-NK 细胞治疗：从临床前与临床图景到合力优化治疗策略

CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.

超越 CAR-T：CAR-NK/T 细胞在血液肿瘤中的兴起

Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.

CAR-NK/T 细胞可能被证明是治疗血液系统恶性肿瘤的一种更安全、更灵活的细胞疗法。

组蛋白去乙酰化酶抑制剂 Entinostat 通过维持 CAR 表达增强 CAR-NK 细胞抗肿瘤活性

Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression.

释放 CAR-NK 细胞的潜力：针对 CD38 阳性恶性肿瘤的有前景的现货型治疗策略

Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies.

体外研究结果表明，抗 CD38 CAR-NK 细胞有潜力作为针对 CD38 阳性恶性肿瘤的现货型治疗策略。

烟酰胺扩增的 CD38 缺失、表达增强型 CD38 嵌合抗原受体的同种异体 NK 细胞靶向多发性骨髓瘤细胞

Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myelo

实体瘤治疗时代的 CAR 细胞疗法：当前挑战与新兴治疗进展

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.